177 delegates took part in the survey, which found that even the most commonly used digital tool, namely automated reminders, are not being used by more than a third of all practices.
Less than 60% are using digital records.
Less than half are using online booking, which Provet says can significantly improve the customer experience.
Less than 20% have implemented integrated payments or telemedicine or pet owner apps.
The survey also found that 42% are still using old server technology, rather than cloud-based solutions (28%).
The company has produced a guide to what you should look for in a practice management system, including pros and cons of cloud vs. server-based solutions and digital tools that can improve service level whilst saving time, which you can download here.
Doxycare is a doxycycline indicated for the treatment of bacterial respiratory tract infections in cats and dogs due to organisms sensitive to doxycycline, and for the treatment of tick-borne Ehrlichia canis infection in dogs. Doxycare is presented in two strengths: 40mg and 200 mg. Both are licensed for use in cats and dogs. The meat-flavoured tablets are scored for quarter splitting to support more accurate dosing.
Metrocare is a metronidazole indicated for the treatment of gastrointestinal tract infections caused by Giardia spp. and Clostridia spp. and the treatment of infections of the urogenital tract, oral cavity, throat and skin caused by obligate anaerobic bacteria. Metrocare is available in two strengths: 250mg and 500 mg. Both are licensed for use in cats and dogs. The meat-flavoured tablets are scored for quarter splitting.
Cephacare, Animalcare’s first-generation cephalosporin, is now also available in a 1000 mg strength meat-flavoured tablet. Cephacare is licensed to treat skin infections, urinary tract infections, respiratory tract infections, digestive tract infections and infections of the oral cavity. The existing 50 mg strength tablet is licensed for use in cats and dogs. The new 1000 mg size tablets are scored to be halved and licensed for use in larger dogs.
James Beaumont, Product Manager, said: "We aim to offer our customers flexible and convenient solutions for the products they need to use every day in practice, while supporting more accurate and responsible dosing. The additions of Doxycare and Metrocare to our range, together with the new 1000 mg Cephacare strength tablet, mean that we are now able to offer a broader range of antibiotics for use in both cats and dogs."
Fiproclear Combo, which contains fipronil and S-methoprene, is licensed for use on cats and dogs and can also be used to treat and prevent fleas and ticks on ferrets.
Norbrook says the new product provides effective protection from new flea infestations for up to eight weeks on dogs and four weeks on cats, while protecting against certain ticks for up to four weeks on dogs, and two weeks on cats.
Monica Whistler, Norbrook Marketing Product Manager, said: "With its triple-action approach, Fiproclear Combo kills adult fleas, ticks and biting lice. The addition of S-methoprene to the already-trusted ingredient fipronil, breaks the flea life cycle in the home by ensuring that any eggs laid by the fleas, which have come into contact with the product are infertile, and by preventing development of flea larvae within a pet’s surroundings.
"Adult fleas on pets are killed within 24 hours whilst newly arrived ticks are killed within 48 hours of attachment – before the main risk period of disease transfer. Ticks rank second only to mosquitoes as insects that spread infectious diseases to both pets and people1; the most common of which is Lyme disease."
Norbrook highlights research which showed almost a third of cats suffered from ectoparasites2, while around one in every three dogs are affected by ticks3, and that many traditional treatments do not help break the flea life cycle in the home.
Monica added: "Typically, by the time an owner notices a flea problem, an infestation has already been present for up to two months. At that point the visible adult fleas on the pet are only part of the problem, with 95% of the parasites already living in the home itself as eggs, larvae and pupae."
References
Merial has launched Merilym 3, the first Lyme disease vaccine available in the UK.
Lyme disease is the most common vector-borne disease in Europe and there has been an increase of over 300% in the number of reported human cases in the UK since 20011. Caused by infection with bacteria from the Borrelia burgdorferi group, the disease is transmitted by Ixodes spp. ticks.
Merial says the vaccine contains inactivated antigens from Borrelia burgdorferi sensu stricto, Borrelia afzelli and Borrelia garinii, so provides broad spectrum immunity against infection. Vaccination with Merilym 3 induces high levels of antibodies against a key bacterial antigen, which are ingested by the tick during blood feeding and subsequently bind to the bacteria in the tick gut, reducing the risk of transmission from the tick to the host.
For use in dogs, the vaccine can be administered to puppies from 12 weeks old, with a primary vaccination course of two injections, three weeks apart, followed by annual boosters. It is available in packs of 10 doses.
For more information, speak to your local Merial Territory Manager.
Reference
The hearing concerned three separate charges against Mr Mallon. The first charge related to his treatment of a Labrador named Bailey on 15 September 2016 in which he was alleged to have euthanased the animal without the owner’s consent, after having been called out to her home following concerns about Bailey’s arthritis.
The second charge related to failure to keep adequate clinical records for Bailey between 14 March 2015 and 30 September 2016.
The third charge related to failing to respond adequately to communications regarding Bailey’s treatment from his owner between 15 September 2016 and 6 January 2017.
At the outset of the hearing, Mr Mallon admitted the charge relating to keeping inadequate clinical records. However, he disputed the College’s evidence regarding euthanasing Bailey without his owner’s consent. He claimed to have had previous discussions with the owner’s husband about euthanasia six months prior to the event, that he had been informed that the owner had mentioned a possible need for euthanasia in a phone call earlier that day and that, on attending the premises, the owner’s mother had mentioned a need to put Bailey down. During the course of the hearing, Mr Mallon accepted that these incidents could not have reasonably amounted to consent.
The Committee also heard and accepted evidence that the owner’s mother, who was present when Mr Mallon visited, had wished to contact her daughter to inform her about the planned euthanasia but that Mr Mallon proceeded to euthanase the animal regardless. The Committee also noted there was no contemporaneous clinical records nor any signed consent form for the procedure. Furthermore, the Committee found no evidence that there was a need to put Bailey down immediately and no reason why Mr Mallon could not have waited until the owner was present and had given consent.
Regarding the third charge, the Committee heard that the communications between Mr Mallon and the owner amounted to a telephone call on 15 September and a letter from the owner dated 16 September in which she asked a number of questions about Bailey’s treatment. The Committee accepted that, during the phone call, the owner had made a number of threats to Mr Mallon that had caused him to be fearful for himself and his property. Furthermore, the Committee found that there were a number of points in the subsequent letter to which he could have responded and the Committee noted that, when he was giving evidence, Mr Mallon expected the owner to apologise to him and withdraw the threats before he would engage with her complaint. The Committee therefore found the charge proved.
After finding the charges proved the Committee then went on to consider whether, individually and cumulatively, they constituted serious professional misconduct. It found this to be the case in respect of all three charges. Commenting on the first charge Jane Downes, chairing the Committee and speaking on its behalf, said: "He should have allowed the owner to come to an informed decision. He had an opportunity to obtain informed consent and he failed in this regard. By failing to take this opportunity he overrode the possibility of allowing [the owner] the right to choose whether to be present or to discuss Bailey’s prognosis."
The Committee then went on to consider the sanction for Mr Mallon and heard from a number of clients and professional colleagues who spoke to his skill, care, passion for animal welfare and high standing in his community. The Committee also considered 30 written testimonials from clients. In mitigation, the Committee also considered Mr Mallon’s otherwise unblemished 30-year career, the fact it was a single isolated event related to one animal and the fact that there was no evidence of systemic or repeated behaviour.
Jane Downes added: "The Committee concluded that the appropriate and proportionate sanction is a reprimand in this case. The Committee is confident that Mr Mallon will not repeat the conduct identified in this case again. The Committee wishes to advise Mr Mallon of the need to reflect on the outcome of this case, the need to have clear communication systems in place at this practice that are effective so as to avoid any possibility of miscommunication. The Committee further advises Mr Mallon of the need to be familiar and comply with all aspects of the Code [of Professional Conduct for Veterinary Surgeons] and its associated guidance, particularly in respect of keeping clinical records, informed consent and effective complaint management."
The acquisition of Jurox brings Zoetis a valuable animal health portfolio, including Alfaxan, a leading anaesthetic product for companion animals and high-quality local R&D and manufacturing operations in Australia.
Stephanie Armstrong, Senior Vice President and Cluster Lead UK, BeNeLuX, Nordics & Ireland, said: “We are grateful to the O’Brien family for entrusting the future of this family-owned business to Zoetis.
"Jurox’s portfolio plays to the strengths of our core business and will be a complementary fit with the solutions we deliver to veterinary professionals, livestock producers and pet owners.
"With Zoetis’ global sales and regulatory expertise in more than 45 direct markets, we look forward to expanding the impact and reach of the entire Jurox portfolio here in the UK and Ireland.”
www.jurox.com
Zoetis has announced the launch of Contacera (meloxicam) 15mg/ml oral suspension, a non-steriodal anti-inflammatory preparation for horses.
According to the company, meloxicam has been shown to hold advantages over Phenylbutazone for the alleviation of musculoskeletal inflammation and pain in horses over six weeks of age1,2,3,4.
Contacera can be mixed with food or syringed directly into the mouth to ensure compliance. It is available in 100ml or 250ml bottles, with a measuring dose syringe and a syringe adaptor. Contacera solution for injection is also available.
Penny McCann, Equine Product Manager, Zoetis UK Ltd, said: "Contacera is an exciting addition to our NSAID portfolio. Due to the potential clinical advantages of Meloxicam, Contacera gives vets an important additional option for NSAID management. It is a logical fit with the other products in our range and benefits from a choice of presentations."
For further information, contact your Zoetis Account Manager, visit www.zoetis.co.uk, or ring Zoetis' Customer Support: 0845 3008034
The idea for an interactive vaccination calendar was in fact first developed two years ago by Jon Reader MRCVS (pictured right) from Synergy Farm Health. With input and funding from Boehringer, it has now been developed into an online tool which highlights times when animals may be at risk if immunity has waned, without sufficient boosting of immunity by vaccination.
The transmission of BVD is complex and protecting the foetus from the virus is at the heart of any control programme. The virus is passed from dam to foetus and, if this occurs in the first third of pregnancy and the foetus goes to term, a persistently infected (PI) calf will be born. These will then go on to shed virus throughout their lives, so infecting herdmates and the next generation of calves.
Jon said: "The timing of when a vaccine is given is critical to the development of an immune response, which will protect the unborn foetus.
"Working out when you want the dam to calve and then calculating back shows when either a primary course of BVD vaccine or a booster should be given but, get this wrong and you will end up with what is known as an 'immunity gap'.
"It is vital that both heifers and cows have maximum protection during the breeding period and in early pregnancy."
Boehringer says heifers must be fully protected before being served for the first time, and cows must have had immunity boosted before they are pregnant again. However, far too often heifers are adequately protected following an initial booster but given their age and date of service, do not receive further protection until they enter the adult herd.
Jon said: "If heifers calve just after the herd booster, then there is a very real possibility that they will go for two years without a booster, and be severely exposed when they become pregnant as a first lactation heifer."
"This is termed the immunity gap; a period when the animal is not protected from the virus at all. The aim should be to eliminate this period completely, so that there is no immunity gap."
Matt Yarnall from Boehringer said: "Each BVD vaccine has its own timing protocol stating when the primary course should be given, as well as subsequent booster timing and when cows should be served. Moreover, some of these are not straightforward to follow, especially for year-round calving herds."
"Anyone using the Bovela vaccine has peace of mind that the one dose primary course combined with flexible booster regime and 12 months’ proven duration of immunity minimises the immunity gap."
For more information, visit: makebvdhistory.co.uk.
The service will be available to veterinary practices that use more than £250/€300 of Royal Canin urinary diets per year.
The company has enlisted the support of an independent laboratory to carry out an infrared spectroscopy analysis of the stones, in order to make a quantitative and qualitative assessment of their composition. Royal Canin says that by appreciating the mineral-type in all layers, the best dietary recommendation can be made.
Lee Danks, Royal Canin’s Veterinary Scientific Support Manager, said: "Managing cat and dog urolithiasis can be challenging. This valuable service will improve practices’ diagnostic capacity, enabling a better understanding of a patient’s condition and a much more individualised approach to treatment and long-term prevention."
Royal Canin says there are many complex and interacting contributors to urinary stone formation1. Dietary modifications can influence urine pH, the concentration of minerals within the urine and most critically, urine turn-over through the bladder2. The many interactions between promotors and inhibitors of urolithiasis highlight just how critical a tailored nutritional approach can be to the long-term health of urinary patients.
Licensed for the treatment of severe equine asthma, each Equipred tablet contains 50mg of prednisolone, a larger concentration tablet designed to make dosing easier.
Equipred tablets are available in boxes of 100 tablets and each tablet can be divided into halves and quarters for accurate dosing and precise tapering of the administered dose.
Rosie Naylor, Equine Technical Product Manager at Virbac said: "We are pleased to add Equipred to Virbac’s equine range. The novel 50mg tablet presentation will enable accurate dosing of horses that require orally administered steroid treatment".
For more information, contact your Virbac Territory Manager.
Corona Detect is a first-line screening tool for detecting exposure to feline coronavirus (FCoV). It can be coupled with the Idexx FIP Virus RealPCR to follow up coronavirus-positive cats exhibiting clinical signs suspected to be FIP. The Idexx FIP Virus RealPCR evaluates for mutations of feline coronavirus to the pathogenic FIPV biotype.
Idexx says that this new two-tier diagnostic approach will help veterinary surgeons rule out or positively diagnose FIP, a condition which has hitherto been extremely difficult and frustrating to diagnose.
Simon Wootton, Idexx’s Companion Animal Group’s Northern European Marketing Manager said: "FIP is a terrible disease, so being able to screen and either confirm or rule out exposure to FCoV is an important additional step in the diagnosis options available to vets. With the ability to screen in minutes, practitioners will be able to decide whether to perform confirmatory and potentially invasive tests for the specific FIPV mutations. This obviously brings benefits to aid pet owners."
Further information is available on the company’s website – www.idexx.eu
The company says VeggieDent Zen provides the same dental benefits as VeggieDent FR3SH Dental Chews, but also includes L-theanine.
L-theanine is an amino acid which Virbac says is known to positively influence GABA levels in the brain to help reduce anxiety and increase mental focus. According to the company, one VeggieDent Zen chew daily can help to calm and reduce anxiety in dogs whilst also providing regular oral care.
VeggieDent Zen is free from GMO corn, wheat, gluten and meat, and contains no colourants or artificial ingredients. The new chews also hold the Veterinary Oral Health Council (VOHC) seal for tartar control.
Claire Lewis, Product Manager at Virbac said: "Dental chews are a great way for pet owners to provide passive dental care at home. With VeggieDent Zen we are pleased to be able to offer pet owners a convenient, multi-functional approach to supporting their pet’s health and well-being."
VeggieDent Zen comes in 4 chew sizes (Extra-Small, Small, Medium & Large) and is available from the veterinary wholesalers now.
For information on VeggieDent Zen, contact your Virbac Territory Manager.
Animals Count, which describes itself as a political party for people and animals, will launch its EU election manifesto on 24th May from 12 noon at the Kings Oak, Loughton, where it will be putting into practice one of its proposed policies: subsidised basic and emergency animal health care for animals. Animals Count President and veterinarian, Andrew Knight, will provide free dog consultations and animal health care advice for all companion animals.
Animals Count will contest the European Parliament elections, taking place on the 4th of June. It hopes to end farming with poor welfare consequences for animals, long distance live animal transport, all hunting for sport, and introduce an EU-wide subsidised basic animal health care system.
Animals Count Leader, Jasmijn de Boo MSc., said: "Concern for animals has long been a mainstream priority, yet remains poorly represented by most political parties. In several countries political parties for animals have formed to meet this need. The Dutch Party for the Animals from which we grew now has 20 elected representatives, including 2 MPs and one senator."
"The EU elections are particularly important for people and animals. Around half the EC budget is spent on agriculture. Given today's economic climate there's never been a better time to re-examine the massive expenditure of tax-payer money on farming methods known to be strongly associated with poor animal welfare and serious environmental damage."
Miss de Boo, 33, Alex Bourke, 47, Vice-chair of Animals Count and best-selling author of the 'Vegetarian Guides' book series, and Richard Deboo, 41, City professional and public speaker on animal issues, will contest the June EU elections in the Eastern region of the UK. Animals Count's ultimate goal is a world in which animals are not exploited, and are treated as sentient beings.
Pill Assist Cat is a soft treat pouch into which you insert a tablet, mould the pouch around the tablet and then feed to the cat.
Royal Canin says that in its tests, tablets were administered to cats successfully in 91% of cases using Pill Assist, which is not far off the 97% achieved with Pill Assist Dog which was launched earlier this year.
Erin Carr, Veterinary Marketing Executive at Royal Canin, said: "It’s an honour to be recognised by such an important industry body.
"Pill Assist Cat is set to launch next year. As with our Pill Assist Dog products, the aim is to make a real difference to pet’s health and wellbeing by turning pill time into a positive experience for both the pet and the owner."
The RCVS has released the photograph of a man apprehended by Wiltshire police whilst working as a bogus veterinary surgeon at a practice in Swindon.
Peter Keniry, who had been practising under the name of a properly qualified and legitimately registered veterinary surgeon Shaun Kehoe, was arrested on 23 August and appeared in Swindon Magistrates' Court on charges of fraud and practising veterinary surgery unlawfully. He was released on bail.
Mr Keniry is no stranger to the College or the police, and has already been dealt with in 1998, 2001 and 2005 for similar offences. On each occasion, Mr Keniry has impersonated a member of the College whose name is legitimately on the Register, which makes it difficult even for practices that do check the credentials of prospective employees.
Gordon Hockey, Head of Professional Conduct and Assistant Registrar at the RCVS said: "We were alerted to the potential fraud on 23 August and immediately liaised with the police to facilitate Mr Keniry's arrest that same day. The next day, RCVS Council member Dr Bob Moore and I visited Swindon police station to assist the police.
"It appears that Mr Keniry has continued his pattern of re-offending, and we hope that by publicising his photograph any other practice that has employed him recently will recognise him and contact the RCVS Professional Conduct Department, and potential employers and locum agencies will keep his photograph to reduce the chances of this happening again."
The RCVS Professional Conduct Department can be contacted on: profcon@rcvs.org.uk or 020 7202 0789.
BVA President Sean Wensley said: "The UK's decision to leave the European Union will have a significant impact on matters of interest to the veterinary profession, particularly in relation to regulation, education, and workforce planning, but also in terms of animal welfare, research, surveillance, and animal movements.
"BVA will work hard to ensure the voice of the veterinary profession is heard during the negotiation and discussions that will now begin, in order to secure the best possible outcomes for our profession and for animal health and welfare in the UK. The Vet Futures report provides an excellent summary of issues we need to consider in those discussions, and the Vet Futures Action Plan, due to be launched at the Vet Futures Summit on 4 July, outlines key initiatives that we need to take forward, albeit with revised timelines while the full impact of Brexit is determined.
"BVA will retain an outward looking and inclusive perspective through our relationships with international partners, including the Federation of Veterinarians for Europe (FVE), Commonwealth Veterinary Association (CVA) and World Veterinary Association (WVA) to ensure the UK veterinary profession continues to influence and engage on cross border issues such as disease surveillance, veterinary medicines and antimicrobial resistance."
The online risk checker, which is available at www.parassess.co.uk, asks pet owners a series of questions to assess their dog's risk from fleas, ticks, lungworm roundworm and tapeworm.
The test, which has been developed with parasitologists, takes a few minutes and appears to produce sensible results (not every test produces a "Danger, high risk, emergency, get to your vet NOW" result, as you might expect if this had been entirely produced bv the marketing department).
The subsequent report can then be shared with the vet to review it and make a treatment decision.
Being online, the test can be taken on a smartphone whilst in the practice waiting room, or on tablet or computer at home.
It might be worth sharing the test with your clients by email or social media, inviting them to book an appointment if their results suggest it is necessary.
To that end, Boehringer Ingelheim has produced a range of communication materials, such as waiting room displays and digital content for web, email, SMS, and social media.
For more information, contact your local Boehringer Ingelheim territory manager or phone 01344 746957 (UK) or 01 291 3985 (Ireland).
Tranquinervin, which contains 10 mg/ml acepromazine, is indicated for anaesthetic premedication, tranquilisation and sedation.
Emma Jennings, Brand Manager at Dechra said: "Tranquinervin provides tranquillisation or a mild sedation for several hours, making it a valuable tool for many day-to-day veterinary scenarios.
"At low doses, acepromazine reduces anxiety which is beneficial for use in horses prior to shoeing or transportation. At higher dose rates, it is an effective sedative for use in situations like dentistry or handling. The relaxant effects also aid examination of the penis in horses and the treatment of tetanus and choke.
"There is also reduced anaesthetic risk reported following sole premedication with acepromazine in healthy horses1."
Tranquinervin is available in a 20 ml vial with a 56 day broached shelf life. It can be used in conjunction with Dechra’s equine anaesthesia and analgesia app which is designed to help you choose optimal anaesthetic protocols and calculate anaesthetic drug doses and administration rates quickly and easily.
For more information, go to: www.dechra.co.uk/products/equine
The company says Euthoxin 500mg/ml is a stronger dose than any other pentobarbital injection products currently available on the UK and Irish markets which means less volume per dose and a better return for veterinary surgeons.
Gareth Carr, commercial manager for Chanelle Vet UK, said: "Our aim is to support UK vets by offering high-quality products at competitive prices.
"We have developed Euthoxin with the veterinarian in mind to offer them a cost-effective, low-volume, reliable euthanasia for a wide spectrum of species."
Euthoxin 500 mg/ml launches officially on 3rd July and will be available from wholesale partners in vials of 100ml.
For further information, download the SPC here, visit www.chanellegroup.co.uk or contact your key account manager for information about a launch offer.
The company’s NEMO Cardiac Health Screening test detects heart disease using AI to analyse microRNAs - biomarkers that manage the immune system and its responses and act as regulators for disease progression or resolution.
MI:RNA says the new test, which can be taken from blood or urine samples, will help vets diagnose and monitor disease progression more effectively and give cats and dogs with heart disease 18 months more life.
Eve Hanks, CEO and founder of MI:RNA (pictured) said: “The use of precision medicine in veterinary diagnostics will help pet owners and breeders alike to ascertain where to direct their efforts and finances accordingly.
"There is massive potential to use this technology to help breeds who have real problems with heart and other diseases, and will consequently help owners and breeders to identify affected animals more quickly.
Professor Joanna Dukes-McEwan, Head of the Cardiology Service at the University of Liverpool said: "From our cardiac investigations, we knew exactly the underlying heart disease and the severity of this, so our data was used as a training set for the MI:RNA panel analysis.
"We have previously collected samples from dogs with myxomatous mitral valve disease and are currently collecting samples from cats with hypertrophic cardiomyopathy.
“I think the MI:RNA panels are most useful for vets in primary care practice to identify and confirm the severity of underlying cardiac disease in their patients.
"A simple blood test which could confirm that the cause of a heart murmur is MVD, and also indicate its severity, and whether the patient would benefit from treatment would be really helpful for primary care vets in practice.
"They might indicate which patients may benefit from referral, or indicate when a specific treatment is indicated.
"Future research with miRNA panels may also indicate novel pathways in progression of disease which might increase our understanding of the disease, or novel therapeutic options.”
The Envirobed cubicle bedding study found that cow comfort is farmers' number one priority, rated 'very important' by 89% and 'quite important' by 9%. A close second, scoring 81% 'very important' and 13% 'quite important', was reducing mastitis bugs. Allied to this, number three was high absorbency bedding, scoring 71% and 16% respectively. Farmers taking part used a variety of different bedding materials.
The importance of reducing humidity in cow housing was also well recognised. To improve ventilation, ridge tiles have been removed by 38% and fans installed by 9% of farmers. Another 18% and 10% respectively are considering these two options.
Sally Russell from Envirosystems points out that keeping cows clean and comfortable doesn't need be compromised by this winter's shortage and high cost of bedding straw: "Although this is driving up the cost of sawdust and some other materials, there are exceptions.
"For example, some farmers with beef cattle and dairy replacements in straw yards are using a deep bed of Envirobed Original, made from 100% dried recycled paper. Others place a 15cm layer on the floor and top it off with straw.
"For cubicles, the usual material of choice is EnviroBed Premium, a blend of dried paper and kiln dried virgin wood sawdust. Per cubicle, the recommended daily quantity and cost are just 1kg at less than 10p."
Envirosystems says both materials are 95% dry matter and mildly alkaline 7.4 pH, helping create a dry and comfortable area that is unfavourable to disease organisms and fly eggs. They are also biodegradeable and compatible with all manure systems.
Envirosystems has given the findings of its research to farming unions, Dairy UK and AHDB Dairy with permission to use the data if it helps them promote an accurate and caring image of farming, contrary to misleading propaganda put about all too often by the industry's numerous critics.
Photo: Comfy Cow, copyright Ivor Davey
Cosacthen contains 0.25 mg/ml of tetracosactide which had only previously been available as human-registered or compounded veterinary ‘special’ preparations meaning availability and cost could be unpredictable.
Tetracosactide is used in the ACTH stimulation test to assess the adrenocortical function of patients with endocrine diseases, such as Cushing’s and Addison’s.
Dechra Brand Manager Claire Morgan said: “As experts in endocrinology, we recognise that the testing involved in adrenal conditions can be a costly process for pet owners, which can mean that some cases don’t progress to treatment or have their treatment optimised.
"The launch of Cosacthen gives veterinary surgeons the reassurance associated with a veterinary licensed medicine. As these cases can appear on an irregular basis, Cosacthen is ideal to keep in the practice ready for when a case is presented making it a cost-effective solution that can help offset the cost for owners of long-term treatment of adrenal conditions."
Cosacthen is available in 1 ml single-use vials.
For more information visit www.dechra.co.uk/cosacthen.
The one hour meeting will take place at 8:00pm on Wednesday 5th May. It will be recorded and available after the event. Simon will begin with a brief background to IR35 and how the system has worked historically. He will then explain what has changed and what the options are for locums (and the impact on their income). The meeting will consider things like the criteria that locums need to fulfill to qualify as sole traders, how to use CEST and alternatives to IR35. There will then be an opportunity to ask questions. All registrants are being invited to submit questions in advance, and the plan is that on the night, groups of four participants will be invited to put their questions to Simon together, in a sort of mini discussion. This'll be repeated as many times as possible within the hour. The meeting is the first in a series planned for VetSurgeon and VetNurse members to meet up, share ideas and make better connections with each other. To register, visit: https://us02web.zoom.us/meeting/register/tZ0rf-GurDIsGdP7UXuJn8TJChZiyXMbdKP_
For more information about Moore Scarrott, see: https://www.moore-scarrott.co.uk
The article points towards the corporatisation of the profession, with 51% of practices now owned by private equity groups and 67% belonging to a group of three practices or more, as the main driver for an increase in vets' fees of over twice the rate of inflation between 2015 and 2020.
However, what the article focuses on, which is the issue of complex and very expensive treatments for pets, is a multifactorial problem which cannot be entirely blamed on corporatisation.
At its heart lie advances in science which now allow vets to offer ever more complex treatments and diagnostics which, when used in human medicine to prolong a human life might sometimes seem expensive, but when used to prolong the life of a dog, can occasionally seem a bit bonkers.
Indeed the article does point towards over-treatment being partly driven by 'celebrity vets advocating increasingly complex surgeries'.
Then there's the fact that both parties to the transaction are often heavily invested in the idea of doing whatever can be done to save the dog: the pet owner, who has anthropomorphised their pet since they first collected it, and the vet, who's entire career has been dedicated to doing their best for the patient in their care.
Then of course there's the inflationary effect of insurance on treatment.
After all, if the animal is insured, why wouldn't you throw the kitchen sink at it?
Things are complicated by the difficulty in estimating the cost of veterinary treatment at the outset, when so much depends on the unknown outcome of diagnostic tests, the progression of disease and the success or failure of treatment. It's not like quoting for a new exhaust system.
There's also the inflationary effect of the increasingly litigious and socially litigious world we live in. It would be no surprise if veterinary surgeons have become more likely to test for everything, when the consequences of missing something is a soul-destroying trial by social media.
And finally, there's the subjective value of money.
Nevertheless, the Daily Mail has a point.
Selling any product or service is about meeting clients' and customers' needs.
If you keep increasing the price of your product range until all you can offer is a Rolls Royce, sooner or later you're going to price yourself out of the market.
One other lesson for the profession from that article: 'No comment' is not a good look for a caring profession.
The RCVS Disciplinary Committee has this week directed that the name of a Grimsby veterinary surgeon should be removed from the RCVS Register, having found him guilty of serious professional misconduct for advising and undertaking surgical procedures without sufficient clinical grounds or considering alternative treatment options; failing to obtain the informed consent of his clients; undertaking procedures outside his area of competence; failing to refer or discuss the option of referral to a specialist; and, failing to provide his patients with adequate pain relief.
Mr Joseph Lennox Holmes, of Waltham Veterinary Clinic, Grimsby, faced nine charges relating to two separate complaints, at a two-week hearing in October which resumed this week.
These complaints concerned four consecutive staphylectomies and a tracheostomy that Mr Holmes performed on Jake, a Cavalier King Charles Spaniel owned by Ms Marsden; the dental treatment he gave to three Persian cats called Dream Topping, Charlie Brown and Henry, together with the advice he gave to their owner, Mrs Auckland.
On 25 October 2007, Mr Holmes performed a staphylectomy on Jake during dental surgery. He gave the Committee various reasons why he thought the procedure was necessary; however, the Committee accepted the opinion of two expert witnesses Professor Dan Brockman, a specialist in soft tissue surgery at the Royal Veterinary College, and Mr Andrew Ash, the senior veterinary surgeon at a 17-vet small animal practice, that there were insufficient clinical grounds for such a surgical procedure to be undertaken. The Committee also found Mr Holmes had not adequately considered other treatments, or obtained fully informed consent from Jake's owner for this procedure.
Mr Holmes performed further staphylectomies and a tracheostomy on Jake, a procedure described by Professor Brockman as "by definition, high risk and best performed by a specialist". He did not consider referral, or inform Mrs Marsden that such referral was an option. Nor did he provide sufficient aftercare or pain relief. Following these surgeries, Jake was euthanased .
In the second complaint, Mr Holmes performed dental extractions on two cats, Dream Topping and Henry, and advised removing teeth from a third, Charlie Brown, in October 2008. The Committee, however, accepted the view of expert witness Mr Ash and Dr David Crossley, RCVS Recognised Specialist in Veterinary Dentistry, that the dental extractions performed, and the advice given, were not justified on the available clinical evidence. The Committee also found that Mr Holmes did not discuss alternative treatment options with Mrs Auckland, or obtain her informed consent. In the case of Dream Topping, consent was sought after the cat had been sedated for an unrelated procedure and Mrs Auckland had felt under pressure to consent.
Mr Holmes had also relied on anaesthesia-inducing drugs to provide analgesia for the dental extractions, without any other form of pain relief. The Committee agreed with the expert witnesses that this was wholly inadequate.
The Committee found many aggravating factors in both cases, including actual injury to animals from unnecessary surgery, and a serious breach of the trust in which Mr Holmes' clients had placed in him to make the welfare of their animals his primary consideration. His repeated misconduct had been sustained over a period of time in the face of a previous adverse finding of the Committee in 2006.
It also found that Mr Holmes failed to appreciate when a case was outwith his experience, and had continued his course of action despite Jake's deterioration; he had not considered referral or accepted that others in the profession might know more than he did; in formulating clinical practice and policies, he made no reference to peer-reviewed literature or continued professional development; and, his use of outmoded drugs and medicines intended for human use was of concern, as was his lack of appreciation of the need for adequate pain relief when performing painful surgical procedures.
Towards the end of the hearing, Mr Holmes said in mitigation that he regretted unreservedly any adverse effects that his treatment had had on the animals concerned, and that he now realised that his long history of working alone had allowed him to become professionally isolated, to become over-confident in the value of his own experience and rather "set in his ways".
Having given serious consideration to postponing judgment, subject to undertakings from Mr Holmes, Disciplinary Committee Chairman Mrs Caroline Freedman said: "We are mindful that the sanction which we apply must be proportionate to the nature and extent of the misconduct found proved and must balance the public interests against the interests of the Respondent.
"We are, however, also mindful of Mr Holmes' conduct during the previous 11½ days of the hearing, during which time his every action was vigorously defended and no insight whatsoever was shown."
The Committee also considered suspending Mr Holmes from the Register. "In view of the serious and long-term nature of the conduct found proved in the charges, we do not feel that it is appropriate that Mr Holmes should be permitted to return to the Register without further assessment of his efforts to update his knowledge," said Mrs Freedman, before concluding: "The only appropriate sanction in each case is that the Registrar be directed to remove Mr Holmes' name from the Register."